These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 37730274

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C, Zheng S, Wang Z, Wang S, Wang X, Yang L, Xu H, Cao Z, Feng X, Xue Q, Wang Y, Sun N, He J.
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer.
    Li R, Salehi-Rad R, Crosson W, Momcilovic M, Lim RJ, Ong SL, Huang ZL, Zhang T, Abascal J, Dumitras C, Jing Z, Park SJ, Krysan K, Shackelford DB, Tran LM, Liu B, Dubinett SM.
    Cancer Res; 2021 Jun 15; 81(12):3295-3308. PubMed ID: 33853830
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hyper-Interferon Sensitive Influenza Induces Adaptive Immune Responses and Overcomes Resistance to Anti-PD-1 in Murine Non-Small Cell Lung Cancer.
    Du Y, Salehi-Rad R, Zhang TH, Crosson WP, Abascal J, Chen D, Shi Y, Jiang H, Tseng YW, Ma X, Hong M, Wang S, Wang X, Tang K, Hu S, Li Y, Ni S, Cai Y, Tappuni S, Shen Y, Liu B, Sun R.
    Cancer Immunol Res; 2024 Dec 03; 12(12):1765-1779. PubMed ID: 39325056
    [Abstract] [Full Text] [Related]

  • 8. CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer.
    Lim RJ, Salehi-Rad R, Tran LM, Oh MS, Dumitras C, Crosson WP, Li R, Patel TS, Man S, Yean CE, Abascal J, Huang Z, Ong SL, Krysan K, Dubinett SM, Liu B.
    Cell Rep Med; 2024 Apr 16; 5(4):101479. PubMed ID: 38518770
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R, Liu C, Zheng S, Wang X, Feng X, Li H, Sun N, He J.
    Cancer Biol Med; 2020 Aug 15; 17(3):768-781. PubMed ID: 32944405
    [Abstract] [Full Text] [Related]

  • 11. Cryoablation triggers type I interferon-dependent antitumor immunity and potentiates immunotherapy efficacy in lung cancer.
    Gu C, Wang X, Wang K, Xie F, Chen L, Ji H, Sun J.
    J Immunother Cancer; 2024 Jan 25; 12(1):. PubMed ID: 38272564
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A, Tomasini P, Souquet-Bressand M, Brandone N, Boucekine M, Grangeon M, Chaleat S, Khobta N, Milia J, Mhanna L, Greillier L, Biemar J, Nanni I, Ouafik L, Garcia S, Mazières J, Barlesi F, Mascaux C.
    J Thorac Oncol; 2019 Jun 25; 14(6):1095-1101. PubMed ID: 30738221
    [Abstract] [Full Text] [Related]

  • 14. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y, Lei Y, Liu L, Zhang S, Wang W, Zhao J, Zhao S, Dong X, Yao M, Wang K, Zhou Q.
    Cancer Med; 2021 Apr 25; 10(7):2216-2231. PubMed ID: 33655698
    [Abstract] [Full Text] [Related]

  • 15. Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy.
    Ndembe G, Intini I, Moro M, Grasselli C, Panfili A, Panini N, Bleve A, Occhipinti M, Borzi C, Garassino MC, Marabese M, Canesi S, Scanziani E, Sozzi G, Broggini M, Ganzinelli M.
    J Exp Clin Cancer Res; 2024 Jan 02; 43(1):6. PubMed ID: 38163906
    [Abstract] [Full Text] [Related]

  • 16. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.
    Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, Atianzar K, Kuo BY, Gardner B, Batra RK, Strieter RM, Dubinett SM, Sharma S.
    Clin Cancer Res; 2004 Apr 15; 10(8):2891-901. PubMed ID: 15102698
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X, Gao A, Zhang F, Yang Z, Wang S, Fang Y, Li J, Wang J, Shi W, Wang L, Zheng Y, Sun Y.
    Theranostics; 2021 Apr 15; 11(7):3392-3416. PubMed ID: 33537094
    [Abstract] [Full Text] [Related]

  • 19. Unveiling the role of KRAS in tumor immune microenvironment.
    Xu M, Zhao X, Wen T, Qu X.
    Biomed Pharmacother; 2024 Feb 15; 171():116058. PubMed ID: 38171240
    [Abstract] [Full Text] [Related]

  • 20. In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade.
    Mao C, Beiss V, Ho GW, Fields J, Steinmetz NF, Fiering S.
    J Immunother Cancer; 2022 Dec 15; 10(12):. PubMed ID: 36460333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.